一分钟看懂
这是一项关于卵巢癌的I 期 / II 期研究，登记的药物或干预包括Torvutatug samrotecan；Saruparib；Bevacizumab；Carboplatin；Palacaparib；Pembrolizumab，当前状态为招募中。登记地点显示中国成都、重庆、广州、济南等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Torvutatug samrotecan；Saruparib；Bevacizumab；Carboplatin；Palacaparib；Pembrolizumab · I 期 / II 期
登记条件中文摘要
年龄范围：18岁至130岁
登记的基本范围为不限性别，年龄18岁至130岁；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Research Site · 成都
- Research Site · 重庆
- Research Site · 广州
- Research Site · 济南
- Research Site · 西安
- Research Site · 郑州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
- * Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of samples for optional genetic research that supports Genomic Initiative. Participants who do not provide informed consent for Optional Genetic Research may still be enrolled in the study.
- * Participant must be ≥ 18 years at the time of signing the informed consent.
- * Willing to provide adequate archival and/or baseline tumor sample as applicable per module-specific criteria.
- * For participants who have previously received targeted therapies such as ADCs, a fresh baseline biopsy will be required unless the most recent archival tissue sample was collected after receipt of such treatment.
- * Eastern Cooperative Oncology Group Performance Status of 0 or 1.
- * Participants with advanced solid tumors must have received prior adequate therapy in accordance with local practice for their tumor type and stage of disease, or, in the opinion of the Investigator, a clinical trial is the best option for the next treatment based on response and/or tolerability to prior therapy. Participants with contraindications or who refuse therapy in accordance with local practice may also be considered provided that it is documented that he/she was informed about all therapeutic options.
- * Participants must have measurable disease per RECIST v1.1,
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05797168；登记信息更新于 2026-10-05；本站同步于 2026-10-08。